Antimicrobial resistance (AMR) is emerging as a critical public health issue worldwide, threatening our ability to treat common infectious diseases.
This phenomenon occurs when bacteria, viruses, fungi, and parasites evolve to resist the effects of medications that once effectively treated them.
Go deeper with GlobalData
As a result, infections become harder to cure, leading to prolonged illness, higher medical costs, and increased mortality.
The misuse and overuse of antibiotics in humans, animals, and agriculture are the key drivers in the increase of AMR.
Understanding and addressing these factors is essential to safeguarding global health and ensuring that effective treatments remain available for future generations.
One prominent example of antimicrobial resistance is methicillin-resistant Staphylococcus aureus (MRSA), a type of bacteria that has developed resistance to several antibiotics.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAccording to leading data and analytics GlobalData’s forecast for the seven major markets (the US, France, Germany, Italy, Spain, the UK, and Japan), there will be approximately 460,000 hospitalised incident cases of MRSA in 2024.
Of these, approximately 77% are expected to be community-acquired MRSA (CA-MRSA), and the remaining 33% are healthcare-acquired MRSA (HA-MRSA).
Unlike HA-MRSA, CA-MRSA spreads easily in community settings such as schools, gyms, and households.
This makes it harder to control and contain the spread of infections.
Additionally, CA-MRSA is problematic because it is difficult to identify the exact source or cause of the infection.
Other challenges brought on by the rise in AMR are higher medical costs and increased mortality.
According to the European Commission, AMR in the EU is associated with €1.5bn ($1.64bn) in extra healthcare costs and productivity loss due to illness.
In the US, the Centers for Disease Control and Prevention and the University of Utah School of Medicine estimate that treating six of the most alarming AMR threats contributes more than $4.6bn in annual healthcare costs.
Treating AMR infections such as MRSA is more expensive than treating non-resistant infections due to the need for more advanced, often costlier, antibiotics.
The prolonged illness and recovery times associated with AMR and MRSA infections lead to lost productivity at work or school.
This has broad economic effects on individuals, businesses, and the economy at large. The higher mortality rates associated with AMR mean more people are dying from previously treatable diseases.
This loss of human life impacts families and communities deeply.
The rising prevalence of these resistant infections represents a dire public health crisis that requires urgent attention and action.
To combat the growing crisis, it is important to implement robust infection prevention measures, promote responsible antibiotic use, and invest in the development of new treatments.
Preserving the efficacy of life-saving medications will ensure a healthier future for all.
